Related references
Note: Only part of the references are listed.Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study
D. Ross Camidge et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Analytical Validation of a Hybrid Capture-Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA
Travis A. Clark et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2018)
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
Neat I. Lindeman et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2018)
Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project
Igor Letovanec et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer
Anne McLeer-Florin et al.
LUNG CANCER (2018)
ALK IHC and FISH discordant results in patients with NSCLC and treatment response: for discussion of the question-to treat or not to treat?
Florian Cabillic et al.
ESMO OPEN (2018)
A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib
Trish Thorne-Nuzzo et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
Solange Peters et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Efficacy of crizotinib in ALK mutant non-small cell lung cancers that are positive by IHC but negative by FISH compared to FISH positive cases
Saurabh Zanwar et al.
INDIAN JOURNAL OF CANCER (2017)
Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non-Small Cell Lung Cancer
A. J. van der Wekken et al.
CLINICAL CANCER RESEARCH (2017)
Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancer
Johanna S. M. Mattsson et al.
BMC CANCER (2016)
A Multiplexed Amplicon Approach for Detecting Gene Fusions by Next-Generation Sequencing
Carol Beadling et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2016)
ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma
Sanja Dacic et al.
ONCOTARGET (2016)
ALK immunohistochemistry for ALK gene rearrangement screening in non-small cell lung cancer: a systematic review and meta-analysis
Jung-Soo Pyo et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS (2016)
BIRC6-ALK, a Novel Fusion Gene in ALK Break-Apart FISH-Negative Lung Adenocarcinoma, Responds to Crizotinib
Ling Shan et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
ALK FISH and IHC You Cannot Have One without the Other
Yasushi Yatabe
JOURNAL OF THORACIC ONCOLOGY (2015)
Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK 'borderline'-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies
M. I. Ilie et al.
ANNALS OF ONCOLOGY (2015)
Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project
Fiona H. Blackhall et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline
Natasha B. Leighl et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Parallel FISH and Immunohistochemical Studies of ALK Status in 3244 Non-Small-Cell Lung Cancers Reveal Major Discordances
Florian Cabillic et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
Garrett M. Frampton et al.
NATURE BIOTECHNOLOGY (2013)
Share Paper
